Xiao Wenbin, Chen Wayne W, Sorbara Lynn, Davies-Hill Theresa, Pittaluga Stefania, Raffeld Mark, Jaffe Elaine S
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Molecular Diagnostic Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Hum Pathol. 2016 Sep;55:108-116. doi: 10.1016/j.humpath.2016.04.019. Epub 2016 May 14.
Hodgkin/Reed-Sternberg (HRS) cells in the setting of chronic lymphocytic leukemia (CLL) exist in 2 forms: type I with isolated HRS cells in a CLL background (Hodgkin-like lesion) and type II with typical classic Hodgkin lymphoma, a variant of Richter transformation (CHL-RT). The clinical significance of the 2 morphological patterns is unclear, and their biological features have not been compared. We retrospectively reviewed 77 cases: 26 of type I and 51 of type II CHL-RT; 3 cases progressed from type I to type II. We examined clinical features, Epstein-Barr virus (EBV) status, and clonal relatedness after microdissection. Median age for type I was 62 years versus 73 years for type II (P=.01); 27% (type I) versus 73% (type II) had a history of CLL. HRS cells were positive for EBV in 71% (55/77), similar in types I and II. Clonality analysis was performed in 33 cases (type I and type II combined): HRS cells were clonally related to the underlying CLL in 14 and unrelated in 19. ZAP-70 expression of the CLL cells but not EBV status or morphological pattern was correlated with clonal relatedness: all 14 clonally related cases were ZAP-70 negative, whereas 74% (14/19) of clonally unrelated cases were ZAP-70 positive. Overall median survival (types I and II) after diagnosis was 44 months. Advanced age was an adverse risk factor for survival, but not histologic pattern, type I versus type II. HRS-like cells in a background of CLL carries a similar clinical risk to that of CHL-RT and may progress to classic Hodgkin lymphoma in some cases.
慢性淋巴细胞白血病(CLL)背景下的霍奇金/里德-斯腾伯格(HRS)细胞存在两种形式:I型为CLL背景中孤立的HRS细胞(霍奇金样病变),II型为典型的经典霍奇金淋巴瘤,即 Richter 转化的一种变体(CHL-RT)。这两种形态学模式的临床意义尚不清楚,且它们的生物学特征也未进行比较。我们回顾性分析了77例病例:26例I型和51例II型CHL-RT;3例从I型进展为II型。我们在显微切割后检查了临床特征、爱泼斯坦-巴尔病毒(EBV)状态和克隆相关性。I型的中位年龄为62岁,II型为73岁(P = 0.01);27%(I型)对73%(II型)有CLL病史。HRS细胞中EBV阳性率为71%(55/77),I型和II型相似。对33例病例(I型和II型合并)进行了克隆性分析:14例HRS细胞与基础CLL克隆相关,19例不相关。CLL细胞的ZAP-70表达而非EBV状态或形态学模式与克隆相关性相关:所有14例克隆相关病例均为ZAP-70阴性,而74%(14/19)的克隆不相关病例为ZAP-70阳性。诊断后的总体中位生存期(I型和II型)为44个月。高龄是生存的不良风险因素,但不是组织学模式,I型与II型相比。CLL背景下的HRS样细胞具有与CHL-RT相似的临床风险,在某些情况下可能进展为经典霍奇金淋巴瘤。